Yorktown Management & Research Co Inc Takes Position in Krystal Biotech, Inc. $KRYS

Yorktown Management & Research Co Inc purchased a new position in Krystal Biotech, Inc. (NASDAQ:KRYS) during the 3rd quarter, HoldingsChannel reports. The firm purchased 2,000 shares of the company’s stock, valued at approximately $353,000.

A number of other institutional investors have also recently added to or reduced their stakes in KRYS. State Street Corp increased its position in Krystal Biotech by 10.5% in the second quarter. State Street Corp now owns 1,355,346 shares of the company’s stock worth $186,306,000 after buying an additional 128,639 shares during the period. Soleus Capital Management L.P. grew its position in shares of Krystal Biotech by 108.9% during the second quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock worth $126,870,000 after acquiring an additional 481,200 shares during the last quarter. Braidwell LP lifted its position in Krystal Biotech by 81.6% in the 2nd quarter. Braidwell LP now owns 727,811 shares of the company’s stock valued at $100,045,000 after purchasing an additional 327,067 shares during the last quarter. Geode Capital Management LLC lifted its position in Krystal Biotech by 1.2% in the 2nd quarter. Geode Capital Management LLC now owns 619,547 shares of the company’s stock valued at $85,174,000 after purchasing an additional 7,194 shares during the last quarter. Finally, Hood River Capital Management LLC boosted its stake in Krystal Biotech by 1.6% during the 2nd quarter. Hood River Capital Management LLC now owns 533,023 shares of the company’s stock valued at $73,269,000 after purchasing an additional 8,379 shares during the period. 86.29% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

KRYS has been the topic of several analyst reports. Zacks Research upgraded shares of Krystal Biotech from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, January 7th. Guggenheim set a $224.00 target price on Krystal Biotech and gave the company a “buy” rating in a research note on Friday, October 17th. Cowen reiterated a “buy” rating on shares of Krystal Biotech in a research report on Friday, January 9th. Weiss Ratings reissued a “hold (c+)” rating on shares of Krystal Biotech in a research note on Monday, December 29th. Finally, Chardan Capital lifted their price objective on shares of Krystal Biotech from $216.00 to $220.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, Krystal Biotech currently has an average rating of “Buy” and a consensus target price of $263.88.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the completion of the transaction, the insider owned 1,413,711 shares in the company, valued at approximately $311,242,613.76. This trade represents a 1.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 13.70% of the company’s stock.

Krystal Biotech Stock Performance

Shares of NASDAQ KRYS opened at $285.04 on Friday. Krystal Biotech, Inc. has a 1 year low of $122.80 and a 1 year high of $295.98. The firm has a market cap of $8.27 billion, a P/E ratio of 42.73 and a beta of 0.46. The stock has a fifty day moving average price of $236.03 and a two-hundred day moving average price of $187.68.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, November 3rd. The company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $1.12 by $1.54. The business had revenue of $97.80 million during the quarter, compared to analyst estimates of $93.72 million. Krystal Biotech had a return on equity of 19.36% and a net margin of 53.30%. On average, research analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.